Pharmaresearch Raises 200 Billion KRW from Global Private Equity Fund

Planned for Use in M&A

Pharmaresearch announced on the 5th that it has decided to conduct a third-party allotment paid-in capital increase to raise approximately 200 billion KRW for operating funds and other purposes.

As a result of the paid-in capital increase, 1,175,647 new shares will be issued. The price per share is 170,119 KRW.

The third-party allotment recipient is 'Polish Company Limited,' a special purpose company established by the European private equity firm CVC Capital. Pharmaresearch plans to use the investment funds for strategic overseas mergers and acquisitions (M&A) and to provide services by establishing local subsidiaries in key markets. Additionally, the investment will be used for research and development (R&D) to develop new products and enhance existing ones.

Pharmaresearch stated, "Considering the securing of partnerships for global expansion, discovery of new growth engines, investor intentions, realization capabilities, and timing, we have finally selected Polish Company Limited."